Cryptotanshinone inhibits ovarian tumor growth and metastasis by degrading c-Myc and attenuating the FAK signaling pathway

Cryptotanshinone (CT), a natural compound derived from Salvia miltiorrhiza Bunge that is also known as the traditional Chinese medicine Danshen, exhibits antitumor activity in various cancers. However, it remains unclear whether CT has a potential therapeutic benefit against ovarian cancers. The aim of this study was to test the efficacy of CT in ovarian cancer cells in vitro and using a xenograft model in NSG mice orthotopically implanted with HEY A8 human ovarian cancer cells and to explore the molecular mechanism(s) underlying CT’s antitumor effects. We found that CT inhibited the proliferation, migration, and invasion of OVCAR3 and HEY A8 cells, while sensitizing the cell responses to the chemotherapy drugs paclitaxel and cisplatin. CT also suppressed ovarian tumor growth and metastasis in immunocompromised mice orthotopically inoculated with HEY A8 cells. Mechanistically, CT degraded the protein encoded by the oncogene c-Myc by promoting its ubiquitination and disrupting the interaction with its partner protein Max. CT also attenuated signaling via the nuclear focal adhesion kinase (FAK) pathway and degraded FAK protein in both cell lines. Knockdown of c-Myc using lentiviral CRISPR/Cas9 nickase resulted in reduction of FAK expression, which phenocopies the effects of CT and the c-Myc/Max inhibitor 10058-F4. Taken together, our studies demonstrate that CT inhibits primary ovarian tumor growth and metastasis by degrading c-Myc and FAK and attenuating the FAK signaling pathway.

[1]  P. Dong,et al.  FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways , 2022, Frontiers in Oncology.

[2]  Runzhi Li,et al.  Astaxanthin from Haematococcus pluvialis ameliorates the chemotherapeutic drug (doxorubicin) induced liver injury through the Keap1/Nrf2/HO-1 pathway in mice. , 2020, Food & function.

[3]  Prakash Kulkarni,et al.  FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials , 2020, Expert opinion on investigational drugs.

[4]  U. Menon,et al.  Ovarian cancer screening: Current status and future directions. , 2020, Best practice & research. Clinical obstetrics & gynaecology.

[5]  Sina Salari,et al.  C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4. , 2019, European journal of pharmacology.

[6]  Sheng Hu,et al.  The double inhibition of PDK1 and STAT3-Y705 prevents liver metastasis in colorectal cancer , 2019, Scientific Reports.

[7]  R. Sears,et al.  Mission Possible: Advances in MYC Therapeutic Targeting in Cancer , 2019, BioDrugs.

[8]  J. Tolson,et al.  A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours , 2019, British Journal of Cancer.

[9]  M. Momeny,et al.  Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status. , 2019, The international journal of biochemistry & cell biology.

[10]  Sarah H. Johnson,et al.  Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low‐Risk From Intermediate‐ and High‐Risk Prostate Cancer , 2019, Mayo Clinic proceedings.

[11]  Philipp M Cromm,et al.  Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation. , 2018, Journal of the American Chemical Society.

[12]  Charles Y. Lin,et al.  Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 , 2018, eLife.

[13]  J. Tolson,et al.  A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098 , 2018, Neuro-oncology.

[14]  Jian Wang,et al.  Sulforaphane regulates apoptosis- and proliferation-related signaling pathways and synergizes with cisplatin to suppress human ovarian cancer , 2018, International journal of molecular medicine.

[15]  V. Thiéry,et al.  Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms. , 2018, Fitoterapia.

[16]  Fei Liu,et al.  Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3/SIRT3 signaling pathway in ovarian cancer cells , 2018, Cancer medicine.

[17]  W. Cong,et al.  A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma , 2018, Current Medical Science.

[18]  Hui Zhou,et al.  Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation , 2018, Science China Life Sciences.

[19]  N. Akhtar,et al.  Plant derived anticancer agents: A green approach towards skin cancers. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  Ž. Bugarčić,et al.  Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. , 2017, European journal of medicinal chemistry.

[21]  P. Dong,et al.  Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells , 2017, Oncotarget.

[22]  V. Margulis,et al.  Integrin signaling potentiates transforming growth factor‐beta 1 (TGF‐&bgr;1) dependent down‐regulation of E‐Cadherin expression – Important implications for epithelial to mesenchymal transition (EMT) in renal cell carcinoma , 2017, Experimental cell research.

[23]  W. Zhai,et al.  Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma , 2017, Oncotarget.

[24]  Zheng Wang,et al.  Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells , 2017, Drug design, development and therapy.

[25]  Weiling Li,et al.  Anti-tumor and chemosensitization effects of Cryptotanshinone extracted from Salvia miltiorrhiza Bge. on ovarian cancer cells in vitro. , 2017, Journal of ethnopharmacology.

[26]  Hening Lin,et al.  A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. , 2016, Cancer cell.

[27]  Shu Zhang,et al.  Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling. , 2016, Biochemical and biophysical research communications.

[28]  S. Dilruba,et al.  Platinum-based drugs: past, present and future , 2016, Cancer Chemotherapy and Pharmacology.

[29]  Bo Yang,et al.  Cryptotanshinone suppresses the proliferation and induces the apoptosis of pancreatic cancer cells via the STAT3 signaling pathway. , 2015, Molecular medicine reports.

[30]  E. Prochownik,et al.  Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. , 2015, Journal of medicinal chemistry.

[31]  A. R. Fernandes,et al.  Organometallic compounds in cancer therapy: past lessons and future directions. , 2014, Anti-cancer agents in medicinal chemistry.

[32]  Xiaoli Ma,et al.  Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells , 2014, Journal of Translational Medicine.

[33]  D. Schlaepfer,et al.  FAK in cancer: mechanistic findings and clinical applications , 2014, Nature Reviews Cancer.

[34]  J. Yue,et al.  A miR-21 hairpin structure-based gene knockdown vector. , 2010, Biochemical and biophysical research communications.

[35]  I. Bahar,et al.  Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. , 2009, Journal of medicinal chemistry.

[36]  V. Golubovskaya,et al.  N-MYC Regulates Focal Adhesion Kinase Expression in Human Neuroblastoma* , 2007, Journal of Biological Chemistry.

[37]  Justis P. Ehlers,et al.  DDEF1 Is Located in an Amplified Region of Chromosome 8q and Is Overexpressed in Uveal Melanoma , 2005, Clinical Cancer Research.

[38]  G. McLean,et al.  Focal adhesion kinase as a potential target in oncology , 2003, Expert opinion on pharmacotherapy.

[39]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[40]  F. Halaweish,et al.  Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B , 2015, Tumor Biology.